EGFR and non-small cell lung carcinoma: Preliminary data from a phase II study (NCT03433469) indicated that neoadjuvant osimertinib (osimertinib 80 mg orally daily for 1–2 months), in surgically resectable EGFR mutant NSCLC, induced pathological responses and downstaging of disease prior to surgery, with a good safety profile [30].